IBIO - iBio, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.1656
+0.0038 (+2.3486%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close0.1618
Open0.1600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1600 - 0.1674
52 Week Range0.1400 - 0.5500
Volume221,393
Avg. Volume1,477,425
Market Cap19.196M
Beta-1.36
PE Ratio (TTM)N/A
EPS (TTM)-0.1750
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • Should iBio Inc’s (NYSEMKT:IBIO) Recent Earnings Decline Worry You?
    Simply Wall St.12 days ago

    Should iBio Inc’s (NYSEMKT:IBIO) Recent Earnings Decline Worry You?

    After reading iBio Inc’s (AMEX:IBIO) latest earnings update (31 December 2017), I found it beneficial to look back at how the company has performed in the past and compare thisRead More...

  • GlobeNewswirelast month

    iBio Selects Lead Candidate for its Fibrosis Therapeutics Program

    NEW YORK, March 14, 2018-- iBio, Inc. announced today that it had selected an E4-Fc fusion protein as its lead candidate for further development of a drug against fibrotic diseases, including systemic ...

  • GlobeNewswirelast month

    iBio Patent Issues in China on Protein Glycosylation Modification

    NEW YORK, March 12, 2018-- IBIO, INC. announced the expansion of its intellectual property portfolio with the issuance of a patent in China describing control of protein glycosylation. The new patent, ...

  • GlobeNewswire2 months ago

    iBio Expands Antibody Development and Production Services to Include Fc Fusion Therapeutics

    NEW YORK, March 07, 2018-- IBIO, INC. announced the expansion of its CDMO capabilities and services to include the development and cGMP manufacturing of Fc fusion proteins for therapeutic pharmaceutical ...

  • iBio Inc (IBIO): Does -31.1% EPS Decline Lately Make It An Underperformer?
    Simply Wall St.4 months ago

    iBio Inc (IBIO): Does -31.1% EPS Decline Lately Make It An Underperformer?

    When iBio Inc (AMEX:IBIO) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...

  • Capital Cube5 months ago

    ETFs with exposure to iBio, Inc. : November 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to iBio, Inc. : November 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • iBio, Inc. :IBIO-US: Earnings Analysis: Q1, 2018 By the Numbers : November 13, 2017
    Capital Cube5 months ago

    iBio, Inc. :IBIO-US: Earnings Analysis: Q1, 2018 By the Numbers : November 13, 2017

    Categories: Yahoo FinanceGet free summary analysis iBio, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of iBio, Inc. – Genocea Biosciences, Inc., Johnson & Johnson, Aviragen Therapeutics Inc, Newlink Genetics Corporation, Altimmune, Inc., Nektar Therapeutics, Achaogen, Inc., Emergent BioSolutions Inc. and Immunomedics, Inc. (GNCA-US, JNJ-US, ... Read more (Read more...)

  • Zacks Small Cap Research5 months ago

    AEMD: Upcoming FDA Meeting Expected to Define U.S. Regulatory Pathway

    Cash used in operating activities was $1.0M in Q2 and $2.1M in 1H 2018.  Relative to the balance sheet, AEMD exited Q2 with $920k in cash but subsequent to quarter-end, they raised $6.0M ($5.3M net) via a secondary equity offering (5.4M shares @ $1.10/share, with 100% warrant coverage: 5yrs, $1.10 strike).  AEMD expects current cash (i.e.

  • ACCESSWIRE6 months ago

    IBio, Aethlon Agreement, The Biologics Market, and Analysts Target, CFB-03 Update

    NEW YORK, NY / ACCESSWIRE / October 23, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • ACCESSWIRE6 months ago

    Featured Company News - iBio Announces Large-Scale Manufacturing Collaboration with Aethlon Medical

    LONDON, UK / ACCESSWIRE / October 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for iBio, Inc. (NYSE: IBIO ), following which we have published a ...

  • PR Newswire6 months ago

    Aethlon Medical Announces Large-Scale Production Collaboration

    SAN DIEGO, Oct. 16, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has established a collaboration with iBio, Inc. (NYSE AMERICAN: IBIO) to support potential large-scale production of the Aethlon Hemopurifier®.  iBio is a leading developer of plant-based biopharmaceuticals. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® to an Expedited Access Pathway (EAP) related to the treatment of life-threatening viruses that are not addressed with approved therapies.

  • What Are The Drivers Of iBio Inc’s (IBIO) Risks?
    Simply Wall St.7 months ago

    What Are The Drivers Of iBio Inc’s (IBIO) Risks?

    If you are a shareholder in iBio Inc’s (AMEX:IBIO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • iBio, Inc. :IBIO-US: Earnings Analysis: Q4, 2017 By the Numbers : October 4, 2017
    Capital Cube7 months ago

    iBio, Inc. :IBIO-US: Earnings Analysis: Q4, 2017 By the Numbers : October 4, 2017

    Categories: Yahoo FinanceGet free summary analysis iBio, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 0.15 million, Net Earnings of USD -4.33 million. Change in operating cash flow of -33.42% compared to same period last year is about the same as change in earnings, likely no significant movement ... Read more (Read more...)

  • Capital Cube7 months ago

    ETFs with exposure to iBio, Inc. : October 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube7 months ago

    ETFs with exposure to iBio, Inc. : September 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)